ClinicalTrials.gg
RecruitingNCT07265349Updated Jan 9, 2026

A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure

A Phase 1/2 interventional study of Mesenchymal stem cells(HucMSCs) and CABG in Coronary Artery Bypass Grafting (CABG), Chronic Heart Failure and Chronic Ischemic Cardiomyopathy, sponsored by Tasly Pharmaceutical Group Co., Ltd. Recruiting at 4 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by Tasly Pharmaceutical Group Co., Ltd (part of China Resources Pharmaceutical Group Limited) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 376 studies in Heart Failure with a site in China — 162 open to participants now, 183 under way, 18 of them phase 3. Heart Failure · China.

Planned enrollment
188th of 246
51 · median 127
Started
2025
with 34 others
Phase 1/2
14 of 376
7 open now
Primary completion
2026-12
later than 81 of 182 live
Registered
319th of 376
by date

Among the 376 studies in Heart Failure with a site in China, this one is the 188th largest by planned enrollment of the 246 interventional ones that give a count, is one of 35 that started in 2025, is one of 14 in phase 1/2, reaches primary completion later than 81 of the 182 other live ones, and was the 319th registered.

Heart Failure

6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

162 of the 376 studies in Heart Failure with a site in China are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 376 studies in Heart Failure with a site in China, or all of them as a file.
02

Study summary

B2278 is a human umbilical cord mesenchymal stem cell (HucMSCs) injection derived from the umbilical cord. It has the advantages of stronger immune regulation, stronger expansion capacity, lower immunogenicity, and greater accessibility. The preliminary research results indicated that the B2278 injection promote the polarization of macrophages towards a reparative state through paracrine action, directly promote angiogenesis and inhibited inflammatory responses, thereby exerting effects on myocardial repair and treatment of heart failure, and it is also safe and well-tolerated.

This trial is a multi-center I/II phase clinical trial of the human umbilical cord mesenchymal stem cell injection solution, aiming to explore the dosage and regimen for the intramyocardial injection of B2278 in combination with coronary artery bypass grafting surgery for the treatment of chronic heart failure caused by chronic ischemic cardiomyopathy, and to evaluate the safety, tolerance and efficacy of allogeneic intramyocardial injection of the human umbilical cord mesenchymal stem cell injection solution in patients with chronic ischemic heart failure.

03

Conditions studied

  • Coronary Artery Bypass Grafting (CABG)
  • Chronic Heart Failure
  • Chronic Ischemic Cardiomyopathy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • 1) Age from 18 to 80 years, both genders are eligible ;
  • 2) Clinically judged to be suitable for CABG treatment due to chronic ischemic cardiomyopathy;
  • 3) (left ventricular ejection fraction) is ≤ 40% as indicated by echocardiography (modified Simpson method) or cardiac magnetic resonance (CMR);
  • 4) (New York Heart Association) cardiac function classification of grade II-IV;
  • 5) Patients or their legal guardians agreed to participate in this trial and signed the form.

Major exclusion Criteria:

  • 1) Severe left ventricular dysfunction, with LVEF ≤ 20% (based on the UCG or CMR examination results during the screening period);
  • 2) Non-ischemic chronic left heart dysfunction, including but not limited to acute left heart dysfunction, dilated cardiomyopathy, severe right heart dysfunction (such as bilateral lower extremity edema accompanied by jugular vein distension, liver enlargement, etc.) or severe pulmonary hypertension (PASP > 70 mmHg);
  • 3) Clinically determined that other surgical procedures need to be performed simultaneously during CABG surgery, including but not limited to congenital heart disease requiring concurrent surgical intervention, heart valve disease, ventricular aneurysm, ventricular septal perforation, papillary muscle dysfunction, aortic dissection, intracardiac mass, thrombus or neoplasm;
  • 4) Acute ST-segment elevation myocardial infarction or stroke event within 1 month before enrollment;
  • 5) Uncontrolled malignant arrhythmia;
  • 6)have undergone or are awaiting heart transplantation or implantation of a left ventricular assist device (LVAD).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
51 participants (estimated)

Study arms

  • Experimental
    CABG combined with low-dose B2278

    CABG combined with B2278 at a dose of 1.0×10\^7 cells per patient, intramyocardial injection into the epicardium

    Drug: Mesenchymal stem cells(HucMSCs)

  • Experimental
    CABG combined with midium-dose B2278

    CABG combined with B2278 at a dose of 5.0×10\^7 cells per patient, intramyocardial injection into the epicardium

    Drug: Mesenchymal stem cells(HucMSCs)

  • Experimental
    CABG combined with high-dose B2278

    CABG combined with B2278 at a dose of 2.0×10\^8 cells per patient, intramyocardial injection into the epicardium

    Drug: Mesenchymal stem cells(HucMSCs)

  • Experimental
    Only CABG

    Only CABG surgery

    Procedure: CABG

Interventions

  • DrugMesenchymal stem cells(HucMSCs)

    B2278 is mesenchymal stem cells derived from human umbilical cord.

  • ProcedureCABG

    only CABG

06

What researchers measure

Primary outcomes

  1. In phase I, primary outcome will be measured with safety events including DLT, AE, SAE, TEAE, and MACE. In phase II, primary outcome will be measured with the change in LVEF based on CMR detection after 6 months of administration.

    Time frame: 6 months

Secondary outcomes

  1. The changes in left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV), and left ventricular end-systolic volume (LVESV) on CMR compared to the baseline.

    Time frame: 6 months

  2. The changes from baseline of LVEF, left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), LVEDV, LVESV on UCG

    Time frame: 28 days, 3 months and 6 months

  3. The proportion of participants with improved LVEF (the proportion of participants whose LVEF increased by ≥10% compared to the baseline and whose LVEF was >40% based on CMR and/or UCG);

    Time frame: 3 months and 6 months

  4. The distribution of the New York Heart Association (NYHA) cardiac function classification

    Time frame: 28 days, 3 months and 6 months

  5. The proportion of participants with NYHA classification ≤ II level

    Time frame: 28 days, 3months and 6months

  6. The changes in the 6-minute walk test (6MWT) results compared to the baseline

    Time frame: 28 days, 3 months and 6months

  7. The changes in the Minnesota Heart Failure Quality of Life Questionnaire (MLHFQ) from the baseline

    Time frame: 28 days, 3months and 6months

  8. The change in the result of amino-terminal pro-brain natriuretic peptide (NT-proBNP) compared to the baseline

    Time frame: 28 days, 3months and 6months

  9. The proportion of participants whose heart failure worsened (requiring hospitalization or emergency treatment due to the aggravation of heart failure symptoms and signs)

    Time frame: 3 months and 6months

Other outcomes

  1. The change in troponin I (TnI) compared to the baseline

    Time frame: 28 days, 3 months and 6months

  2. The changes from the baseline of high-sensitivity C-reactive protein (hs-CRP), TNF-α, IL-1, and IL-6

    Time frame: 28 days, 3 months and 6 months

  3. The changes in perfusion and metabolism of ischemic myocardium during the injection stage as measured by myocardial nuclear imaging (SPECT + PET) compared to the baseline (applicable only to those who have undergone nuclear imaging for determination)

    Time frame: 6 months

07

Study locations

2 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 43 phase 1/2 interventional studies under Heart Failure, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 48. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2025
First posted
Dec 4, 2025
StartActual
Dec 26, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Aug 1, 2027
Last update
Jan 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07265349
Collaborators
Ruijin Hospital
Responsible party
Sponsor
First posted
Dec 4, 2025
Start date
Dec 26, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Jan 9, 2026

Study contacts

Qiang Zhao
Contact
Zq11607@rjb.com.cn
86+13701695256

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion